Roivant Sciences Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Roivant Sciences Ltd.
Dermavant’s Vtama Appears Well Positioned To Compete With Other Topicals In AD
Approved for psoriasis, Vtama met the primary and secondary endpoints in first of two Phase III atopic dermatitis studies. The Roivant affiliate will position the drug as a two-in-one solution for both.
Finance Watch: Structure Launches Third And Largest US Biopharma IPO Of 2023
Public Company Edition: Structure Therapeutics’ upsized initial public offering raises $161.1m, surpassing proposed terms for up to $134.3m. Also, Pliant capitalizes on good data with a $287.5m follow-on offering, while Magenta seeks strategic alternatives and Instil reveals more job cuts.
Roivant Is Striving Towards New Standards Of Care
With numerous highly anticipated data readouts due over 2023, the spotlight is on Roivant like never before. CEO Matt Gline enlightens In Vivo on the firm’s ‘vant’ subsidiaries, its in-house drug development strategies and the future of its Vtama psoriasis treatment.
Finance Watch: SPAC Deals Stumble, Layoffs Continue As Valuations Struggle To Recover
Aesther Healthcare Acquisition extended the deadline to merge with Ocean Biomedical, while Intrinsic Medicine no longer plans to go public by merging with a SPAC. In restructuring news, Otonomy begins liquidation, Celyad cuts last clinical program with cash running out and Clovis files for bankruptcy.
- Large Molecule
- Other Names / Subsidiaries
- Altavant Sciences
- Aruvant Sciences
- Axovant Sciences
- Cyotvant Sciences
- Dermavant Sciences
- Immunovant Sciences
- Metavant Sciences
- Roivant Health
- Roivant Neurosciences Ltd
- Roivant Pharma
- Roivant Sciences Ltd.
- Sinovant Sciences
- Sumitovant Biopharma Ltd.
- Valor Biotechnology
- Axovant Gene Therapies Ltd.
- Kinevant Sciences
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.